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Background: Studies in orphan diseases are, by nature, confronted with small patient populations, meaning that
randomized controlled trials will have limited statistical power. In order to estimate the effectiveness of treatments in
orphan diseases and extrapolate effects into the future, alternative models might be needed. The purpose of this study is
to develop a conceptual disease model for Pompe disease in adults (an orphan disease). This conceptual model describes
the associations between the most important levels of health concepts for Pompe disease in adults, from biological
parameters via physiological parameters, symptoms and functional indicators to health perceptions and final health
outcomes as measured in terms of health-related quality of life.
Methods: The structure of the Wilson-Cleary health outcomes model was used as a blueprint, and filled with clinically
relevant aspects for Pompe disease based on literature and expert opinion. Multiple observations per patient from a
Dutch cohort study in untreated patients were used to quantify the relationships between the different levels of health
concepts in the model by means of regression analyses.
Results: Enzyme activity, muscle strength, respiratory function, fatigue, level of handicap, general health perceptions,
mental and physical component scales and utility described the different levels of health concepts in the Wilson-Cleary
model for Pompe disease. Regression analyses showed that functional status was affected by fatigue, muscle strength
and respiratory function. Health perceptions were affected by handicap. In turn, self-reported quality of life was affected
by health perceptions.
Conclusions: We conceptualized a disease model that incorporated the mechanisms believed to be responsible for
impaired quality of life in Pompe disease. The model provides a comprehensive overview of various aspects of Pompe
disease in adults, which can be useful for both clinicians and policymakers to support their multi-faceted decision making.
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Research in rare diseases is complicated by several
methodological difficulties, which especially arise from
insufficient statistical power due to low patient num-
bers [1]. Despite these methodological difficulties, policy
makers require information on the burden of the disease
and the therapeutic value of orphan therapies to support
their decisions on reimbursement [2]. This information is
especially important because orphan therapies are often* Correspondence: kanters@bmg.eur.nl
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ing to up to €600,000 per patient per year for some orphan
drugs [3].
In the absence of long-term follow-up data on sufficiently
large numbers of patients – as is the case for many orphan
diseases – conceptual models can be used to describe the
disease and assess treatment benefits. Such models allow
the extrapolation of outcomes based on relatively short-
term follow-up data of a limited number of patients, by
combining available data with known disease-specific
correlations.
The conceptual model developed by Wilson and Cleary
(1995) provides a conceptual framework. It describes the
relationship between different aspects of the disease (fromis distributed under the terms of the Creative Commons Attribution 4.0
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and overall quality of life [4]. The Wilson-Cleary model
consists of five distinct levels of health concepts: 1) bio-
logical and physiological factors, focusing on the function
of cells, organs, and organ systems; 2) symptom status, the
patient’s perception of an abnormal physical emotional or
cognitive state, including, for instance, fatigue, worry and
depression; 3) functional health, the ability of the individ-
ual to perform particular defined tasks; 4) general health
perceptions, a patient’s subjective rating of an integrated
concept of all health aspects; and 5) overall quality of life,
the individual’s state of overall well-being. The model
combines clinical and social science models by categoriz-
ing health outcomes into underlying health concepts and
by identifying causal relationships between the different
concepts. As such, the model describes a causal pathway
from clinical outcome parameters to quality of life. The
model can be used to estimate quality of life on the basis
of patients’ clinical data.
Pompe disease is an inherited, metabolic orphan disease.
It is caused by a deficiency of the enzyme alpha-glucosidase
needed for the degradation of lysosomal glycogen, and leads
to storage of glycogen in many tissues [5]. Pompe disease
has a broad clinical spectrum. The severe, classic infantile
form is accompanied by muscle and heart malfunctioning,
leading to death within the first year of life [6–8]. The ma-
jority of Pompe patients (~80 %) present at adult ages with
muscle weakness. Limb girdle and respiratory muscles are
predominantly affected [8–10]. Eventually, most patients
require ambulatory and respiratory support and life expect-
ancy is decreased compared to the general population [11].
Enzyme replacement therapy (ERT) with alglucosi-
dase alfa has proven to be effective in Pompe disease
[12–15]. Treatment of adult patients with Pompe disease
with ERT is lifelong and associated with annual costs of up
to €382,000 per patient [3]. Such high treatment costs
potentially translate in a high incremental cost-effectiveness
ratio.
To support reimbursement decisions, information on the
burden of disease in untreated patients is needed, as well
as on the effect of treatment and its cost-effectiveness.
Ultimately, a model to estimate the cost-effectiveness of a
treatment requires information on survival and quality of
life in both treated and untreated patients as well as on the
costs of treatment.
The purpose of this study is to develop a conceptual
model for Pompe disease in adults and statistically test it
in untreated patients. The structure of the conceptual
model was established by applying the concept of the
Wilson-Cleary model to Pompe disease, describing the
associations between biological and physiological variables,
symptoms, functional status, general health perceptions
and health-related quality of life for this disease. The
model can be used to predict health outcomes and canalso be the starting point of a cost-effectiveness model, if
information about disease progression, treatment effects
and costs are added to it.
Methods
Part 1: Application of the Wilson-Cleary model to Pompe
disease
Modelling guidelines prescribe extensive consultations
with clinical experts in the development of a model [16].
Therefore, variables were included in the draft conceptual
model for Pompe disease based on clinical relevance, as
derived from clinical expert opinion and review of the
literature. The model was discussed with experts from the
Dutch Center of expertise for Pompe disease repeatedly
until consensus was reached on the draft model. Next, the
selected variables were assigned to the different levels of
health concepts of the Wilson-Cleary model.
Part 2: Statistically testing of the relationships of the
model
To come to a final conceptual model, the relationships
between the different levels of health concepts of the
draft conceptual model were quantified in the second
part of the study. In line with modelling guidelines,
which recommend that a conceptual model should not be
driven by data availability [16], clinical plausibility rather
than statistical significance of an association determined
whether variables were included in the final model.
Study sample and data collection
The study population consisted of patients with a proven
diagnosis of Pompe disease by enzyme analysis and/or
mutation analysis. Data was collected between January
2005 and January 2011. During this period, 103 adult
Pompe patients were followed at Erasmus Medical Center
in Rotterdam, the Dutch national center of expertise for
Pompe disease. Clinical data was collected during regular
standardized follow-up examinations at the Erasmus
Medical Center. Patient reported outcome data were ob-
tained from the ongoing International Pompe Association
(IPA) survey in which all Dutch patients participate [11]
and a burden of illness study in Pompe disease in adults
[17]. The dataset consisted of multiple observations per
patient, obtained at irregular time intervals and with a
variable number of observations per patient. Only data
on adult patients who were untreated at the time of
observation were included in the analyses. No other
inclusion criteria were applied; meaning that all adult
patients diagnosed with Pompe disease were eligible for
inclusion in the study, from mild to severely affected
patients. Only patients for which data was available on at
least two adjacent levels of health concepts were included
in the regression analyses. All patients provided informed
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Ethics Committee of Erasmus MC.
Statistical analyses
We explored the strength of the relationships depicted in
the conceptual model by means of random effects linear re-
gression analyses. The regressions estimate relationships for
a cross sectional unit during a particular time. Explanatory
variables and dependent variables are dated at the same
point in time (e.g. functioning at t = 1 is used to model
general health perceptions at t = 1) [18]. The regression
analyses account for interdependence of multiple observa-
tions per patient. The analyses represent cross-sectional
analyses on multiple observations per patient. A separate
regression analysis was run for each relationship between
levels of health concepts in the conceptual model. In total
eight different sets of analyses were performed, shown as
models I to VIII in the results section. The different levels
of health concepts of the conceptual model were first used
as dependent variables in the regression analyses and subse-
quently as explanatory variables in the model for the next
level. Levels of health concepts in the model (i.e. biological
and physiological variables, symptom status, functional
status, health perceptions and quality of life) could entail
multiple variables. For each regression model, the com-
bined significance of all variables was tested by means of a
Wald Chi square test. The number of patients and ob-
servations per patient varied in the different regression
analyses. The significance level was set at p = 0.05. The
percentage of variance explained by the model was
assessed by the overall R2 of the regression models.
Statistical analyses were performed using Stata version
13 (StataCorp, 2013).
Results
Part 1: Development of a conceptual model for Pompe
disease based on the Wilson-Cleary model
Biological and physiological variables
The first level of health concepts of the Wilson-Cleary
model essentially describes two aspects: biological factors
and physiological factors. In the conceptual model for
Pompe disease, these were disentangled to allow modeling
of the relationship between the biological cause of Pompe
disease and physiological variables. Reduced activity of the
enzyme acid alpha alglucosidase is the biological cause of
Pompe disease [5]. We therefore included enzyme activity
(measured in fibroblasts as a percentage of enzyme activity
of non-Pompe patients) in the model as a biological
variable.
With respect to physiological aspects, experts proposed
the use of skeletal muscle strength and respiratory function
[8, 13, 19–21]. Skeletal muscle strength was assessed by
manual muscle testing using the grading scale from 0 (no
visible contraction) to 5 (normal strength) of the MedicalResearch Council (MRC). For selected muscle groups, the
MRC scores were summed, and subsequently the MRC
sum score was expressed as a percentage of the maximum
possible score (as described in [22]). Respiratory function
was measured using forced vital capacity (FVC) in sitting
position. Results were expressed as a percentage of the pre-
dicted normal value derived from published data [23].
Symptom status
The second level of health concepts in the Wilson-Cleary
model covers symptoms. Adult Pompe patients have been
shown to experience fatigue [24, 25]. Shortness of breath
is another symptom frequently experienced by Pompe
patients [26]. Therefore, fatigue and shortness of breath
were proposed to reflect symptom status in the draft
conceptual model. Fatigue was assessed using the Fatigue
Severity Scale (FSS), which examines the self-reported
effects of fatigue on daily functioning [27]. The scale ranges
from 1 (no fatigue) to 7 (extremely fatigued), with a score
of 4 or higher indicating that a patient is fatigued. Shortness
of breath was not assessed in this patient population. Since
no data were available on shortness of breath, a direct rela-
tionship between physiological variables (MRC sum score
and FVC) and functional status was included in the model
explaining functional status, in addition to FSS.
Functional status
The third level of health concepts in the Wilson-Cleary
model is functional status. The self-reported nine item
Rotterdam Handicap Scale (RHS) was considered to be a
suitable measure of functional status. The RHS measures
participation in daily life of patients and comprises 9 items
that can be scored from 1 (unable to fulfill the task or
activity) to 4 (complete fulfillment of the task or activity)
[28]. The RHS score ranges from 9 to 36, with lower levels
of handicap being associated with higher RHS scores.
Hagemans et al. (2007) applied the RHS in Pompe disease
and showed that daily life was substantially affected by the
disease, especially with respect to job/study performance
and ability to fulfill domestic tasks [29].
General health perceptions
The fourth level of health concepts of the Wilson-Cleary
model includes general health perceptions, characterized by
Wilson-Cleary as 1) an integration of the health concepts
discussed above plus others (such as mental health) and 2)
being a subjective rating. Two patients can objectively have
the same health state but may have a very different per-
ception of their health, potentially because of differences
in factors like coping or self-efficacy. Health perceptions
can be measured using the EQ-5D Visual Analogue Scale
(EQ-5D VAS) [30]. Patients indicate their perceived health
status on a thermometer ranging from 0 (worst perceived
health status) to 100 (best perceived health status).
Table 1 Patient characteristics at baseline
Number of patients N Mean Min Max
Age (years) 79 49.3 23.0 72.6
Gender (female) 79 50.6 %
Duration since diagnosis (years) 79 8.0 0.0 27.5
Enzyme activity (% of normal) 79 12.4 0.5 19.9
Muscle strength (% predicted) 64 82.1 48.3 100.0
Respiratory function (% predicted) 63 76.1 11.3 123.4
Fatigue Severity Scale 61 5.6 2 7
Rotterdam Handicap Scale 64 27.4 13.5 36.0
Visual Analogue Scale 49 65.0 30.0 95.0
Mental Component Scale 60 53.8 24.2 74.0
Physical Component Scale 60 35.4 17.6 53.3
EQ-5D Utility 50 0.736 0.201 1.000
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The final level of health concepts of the Wilson-Cleary
model is quality of life (QoL). Previous studies have shown
that QoL is lower in patients with Pompe disease compared
to the general Dutch population [17, 21, 31]. QoL can be
measured using the Mental Component Scale (MCS) and
Physical Component Scale (PCS) of the Short-Form 36
(SF-36) [32] as well as in utilities derived from the EQ-5D.
Utilities range from 0 (representing death) to 1 (represent-
ing perfect health). The SF-36 is a validated instrument to
describe a patient’s health status [33]. MCS and PCS can
be constructed from the eight distinct domains of health
derived from the SF-36. U.S. norm based scores were used
to compute PCS and MCS [32]. Two studies showed that
PCS was significantly lower in patients with Pompe disease
compared to the general population, but found that MCS
was not affected by the disease [21, 31]. The SF-36 reflects
a patient’s self-reported health status, whereas a utility
provides a valuation of health based on the perceived
importance of different domains by the general public. In
our study, utilities were derived from the widely used EQ-
5D [30], a validated tool to measure quality of life. The
Dutch tariff was used to calculate utilities [34].
Characteristics of the individual and the environment
We hypothesized that age, gender and disease duration
(time since diagnosis) could be used as individual patient
characteristics potentially affecting all levels of health
concepts in the conceptual Pompe disease model, except
for the biological level [20, 21, 35–38].
Part 2: Quantification of the relationships in the draft
conceptual model
Study population
For 79 patients (77 % of the total Dutch adult Pompe
population) who did not receive ERT data was available
on at least two adjacent levels of health concepts. Half of
the population was female, average age at baseline was
49.6 years and baseline disease duration since diagnosis
was 8.0 years (Table 1). The maximum follow-up period
was 5.4 years while the median follow-up was 1.1 years.
The maximum number of observations per patient was
12. The median number of observations per patient was
two and ten patients had only a single observation.
Quantitative evaluation of the draft conceptual model
Table 2 presents the results of the multivariate regression
models. Models I (MRC sum score as the dependent
variable) and II (FVC) describe physiological variables,
model III (FSS) represents symptom status, model IV
(RHS) represents functional status, model V represents
health perceptions (EQ-5D VAS), and models VI, VII
and VIII (MCS, PCS and Utility respectively) describe
quality of life.Models predicting the physiological level of health concepts
(models I and II)
The MRC sum score was negatively associated with disease
duration (p < 0.001). One additional year with the disease
was associated with a 0.6 % point reduction in the MRC
sum score. FVC was not associated with disease duration
(p = 0.190). The MRC sum score and FVC were not related
to age (p = 0.411 and p = 0.459, respectively). However, if
disease duration was not included in the model, age was
significantly related to MRC sum score (0.240 percentage
points decrease per year; p = 0.005), but age was not signifi-
cantly related to FVC (p = 0.135). Female patients had a
higher FVC (by 18.0 percentage points) than males (p =
0.001) but there was no difference between males and
females in MRC sum scores (p = 0.990). Only baseline
observations were available for enzyme activity and
were assumed constant for later observations. Baseline
enzyme activity was not significantly related to muscle
strength (p = 0.215) or respiratory function (p = 0.556).
Model predicting the symptom status level of health
concepts (model III)
FSS was negatively associated with disease duration
(p < 0.001). One additional year with the disease was
associated with a 0.08 point decrease of FSS. FSS was
not associated with age (p = 0.389), gender (p = 0.382),
enzyme activity (p = 0.893), or FVC. FSS was associated
with the MRC sum score only at a 10 % significance level
(p = .070).
No data on shortness of breath were available for this
population.
Model predicting the functional status level of health
concepts (model IV)
RHS was significantly affected by FSS (p < 0.003). Every 1
point increase in FSS was associated with a decrease of 0.5
in handicap scores. Furthermore, RHS was significantly
Table 2 Regression coefficients based on a random effects model
Level Physiological variables Symptom status Functional status Health perceptions Health related quality of life
Model I MRC II FVC III FSS IV RHS V EQ-5D VAS VI MCS VII PCS VIII Utility
Constant 83.452 70.526 8.737 16.989 −9.313 49.990 24.526 0.530
Age −0.069 −0.144 0.011 −0.096 0.126 −0.016 −0.046 0.001
Female −0.028 17.994 0.307 −0.957 4.673 −1.282 −0.402 0.010
Disease duration −0.563 −0.346 −0.077 −0.052 0.653 0.063 −0.086 −0.001
Enzyme activity 0.370 −0.431 0.007 −0.048 0.004 −0.359 −0.069 −0.006
Muscle strength −0.031 0.189
Respiratory function −0.011 0.075
Fatigue Severity Scale −0.578
Rotterdam Handicap Scale 2.030
Visual Analogue Scale 0.157 0.223 0.004
patients 78 72 61 61 73 73 73 71
observations 249 257 160 158 154 152 152 161
R2 (overall) 0.105 0.075 0.322 0.623 0.343 0.183 0.293 0.354
Wald test (p-value) <0.001 0.001 0.002 <0.001 <0.001 0.005 <0.001 <0.001
Figures in bold indicate significance at 5 % level; Enzyme activity, muscle strength and respiratory function were measured as a percentage of normal values,
Visual Analogue Scale, Mental Component Scale and Physical Component Scale were measured on a scale from 0–100, Fatigue Severity Scale was measured on a
scale from 1–7, Rotterdam Handicap Scale was measured on a scale from 0–36, Utility was measured on a scale from 0–1
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Every 1 % point increase in MRC sum score (FVC)
was associated with an improvement of 0.2 (0.1) in
handicap scores. Age also had a significant association
with handicap scores in that older patients had poorer
scores than younger patients (0.1 points per year in-
crease in age; p < 0.004). Gender, disease duration and
enzyme activity were not significantly associated with
RHS scores.Model predicting the general health perceptions level of
health concepts (model V)
The EQ-5D VAS was significantly associated with Rotter-
dam Handicap Scale (p < 0.001). An increase of 1 point in
RHS score translated in an increase in EQ-5D VAS of 2
points. Disease duration was also positively associated to
EQ-5D VAS (p = 0.002). Age, gender and enzyme activity
were not related to EQ-5D VAS.Models predicting the health related quality of life level of
health concepts (models VI, VII and VIII)
MCS was not significantly associated with age, disease
duration, gender, enzyme activity. MCS was significantly
associated with the EQ-5D VAS (p < 0.0001); a 1 point
increase on the EQ-5D VAS would lead to an increase in
MCS of 0.2.
PCS was associated with EQ-5D VAS (p < 0.001); a 1
point increase in EQ-5D VAS would result in an increase
of the PCS with 0.2 points. PCS was not affected by age,
gender, disease duration and enzyme activity.Utility was significantly and positively associated
with EQ-5D VAS (p < 0.001). An increase with 1 point
on EQ-5D VAS leads to an increase in utility of 0.004.
Utility was not associated to age, gender, disease dur-
ation or enzyme activity.
Figure 1 presents the final conceptual model for
Pompe disease. The conceptual model can be used to
predict quality of life by inserting clinical data in the
formulas found in the various models (as depicted in
the Additional file 1: Figure S1). In this respect, it
should be noted that the estimated coefficients from
the regression analyses (Table 2) are all surrounded
with varying amounts of uncertainty, which is pre-
sented in the Additional file 1: Figure S1.Discussion
It has often been stated that the common methodology
for clinical and cost-effectiveness studies is unsuitable for
orphan diseases, due to the limited number of patients
[1, 39]. One recurring problem stemming from the
low disease frequency is limited statistical power. A
disease model can be used when long-term follow-up
is unavailable. The concept of a disease model incor-
porates disease progression based on a combination
of clinical plausibility and statistical analysis. Here
we present a disease model for Pompe disease. Em-
pirical data was used to test the relationships in this
model. The model forms a starting point, to which
information about treatment effects can be added in
the future.
Fig. 1 Wilson-Cleary conceptual disease model applied to Pompe disease
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We set out to describe the natural course of Pompe disease
using an application of the Wilson-Cleary model. The ap-
propriate structure of the model is disease dependent.
For some disease progression models, classification of
disease states is feasible (e.g. cancer, arthritis, multiple
sclerosis, heart disease). Pompe disease is characterized
by a continuous range of phenotypes, which makes identi-
fication of disease states difficult. Furthermore, accurately
estimating parameter values for disease states is hampered
by small sample sizes. Therefore, we applied the Wilson
Cleary conceptual model rather than a model containing
health states. Content validity (i.e. the validity of the associ-
ations that were modelled) of this model is ensured by the
clinical experts that were involved in the development of
the model and evidence from the literature. By comparing
the results of the final model to findings reported in the
literature construct validity can be assessed. Such compari-
sons reveal that the conceptual model is largely supported
by the data since many of the results correspond with find-
ings from previous studies. Disease duration is negatively
associated with MRC sum score, in line with earlier find-
ings [21, 35, 36]. The rate of MRC sum score deterioration
(0.6 % points per year) is comparable to our previous publi-
cations [22, 38]. No significant association between disease
duration and FVC was found (p = 0.190), in contrast to
findings described earlier [20, 35, 36]. However, the rela-
tively small though nonsignificant p-value we found in our
analysis may be an indication of limited statistical power, a
reduced ability to detect an existing association. Female
patients have higher FVC than male patients, which is
similar to the findings of our earlier study [20]. Enzyme
activity is not associated with the MRC sum score or
FVC, which agrees with the findings of earlier studies that
did not find any relationship between enzyme activity and
severity in adult patients [8, 36]. Being the underlyingbiological explanation of the disease, enzyme activity is
retained in the conceptual model, despite the absence of a
statistical significant association with other variables in
the conceptual model.
The genetic mutation is the underlying cause of reduced
enzyme activity. However, in our population most of the
patients have the same mutation. Hence, mutation is left
out of the model.
FSS was not associated with MRC sum score or FVC,
albeit that FSS was significantly related to MRC at the 10 %
level (p = 0.070). Our previous studies did not find a
relationship between fatigue and muscle strength and
pulmonary function for adult patients with Pompe dis-
ease. While more severely affected patients (i.e. those
who are in a wheelchair and/or ventilator dependent)
do report higher FSS scores, almost all patients report
fatigue [24, 40]. For example, 71 % of patients who did not
use respiratory support and/or wheelchair reported a FSS
score of more than 4 (reflecting fatigue), while 59 % had an
FSS score of more than 5 (reflecting severe fatigue). Also,
even when patients are still in the pre-clinical stage of the
disease they can report fatigue.
RHS is significantly affected by MRC sum score and FVC
and better performance on these physiological variables are
reflected by lower handicap scores. These findings resemble
earlier results that showed that severely affected patients
(that is, those requiring ambulatory and respiratory sup-
port) reported lower scores on RHS than other patients
[29]. The significant relationships indicate that functional
status is not fully explained by fatigue, but by other prob-
lems related to reduced skeletal muscle strength and
pulmonary function as well. One of these problems could
be shortness of breath, which was absent in the model due
to lack of data.
The conceptual model we present here embodies the
current state of knowledge on Pompe disease in adult
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used to fine-tune the relationships in the model. Moreover,
new insights in the measurement of respiratory function
might lead to the replacement of FVC by maximal inspira-
tory pressure (MIP) or maximal expiratory pressure (MEP).
Inclusion of shortness of breath in new versions of the
model might be reconsidered if new insights or analyses
become available in future. Similarly, a newer version of the
model can include once such data are available.
Strengths and applicability of the model
The availability of a (large) cohort of Pompe patients with
several outcome measures enabled statistical testing of the
conceptual model. Moreover, the dataset is relatively large
compared to other orphan diseases, with available data on
79 patients and multiple observations for most patients.
Although the current statistical analyses were based on
Dutch patients only, there are no indications that the
disease processes differ between the Dutch population and
patients in other countries. Therefore, the underlying
conceptual relationships described in the model will also
be valid in other settings. The results described in this
paper are also transferable for use in other countries since
the measurement techniques (e.g., to describe muscle func-
tion) are widely used and not country-specific.
For many other orphan diseases, the number of patients
is too small for a single institution or even a single country
to assess a drug’s effectiveness. Data from international dis-
ease registries can potentially be used to explore relation-
ships between clinically relevant levels of health concepts of
an orphan disease. The testing of longitudinal relationships
requires systematic follow-up, which might not yet be avail-
able in orphan disease registries.
The use of random effects models appears particularly
beneficial in orphan diseases since it can compensate for
the low number of patients to a certain extent. For this
purpose, the availability of multiple observations per patient
is indispensable.
Treatment
The assessment of a treatment effect is outside the scope of
the current study. The analyses were deliberately restricted
to untreated patients because we aimed to develop a model
that describes the conceptual intercorrelations between the
various levels of health concepts for Pompe disease. How-
ever, the conceptual model could be seen as a starting point
for developing a full cost-effectiveness model to evaluate
the cost-effectiveness of enzyme replacement therapy,
assuming that the causal pathway of the disease will not
change. Enzyme replacement therapy supplements the low
levels of enzyme and has been shown to influence various
levels of health concepts in the model, i.e. muscle strength
and respiratory function, fatigue, functional health and
quality of life, presumably through the supplementation ofenzyme [13, 22, 40–42]. If the model would in the future
be used to estimate effects of ERT on health outcomes, this
could be done in several ways. One way is to apply relative
risk reductions to the outcomes as predicted by the equa-
tions in the model. These risk reductions would reflect the
effect of ERT. Another approach is to re-estimate the equa-
tions with ERT as a predictor in the regression models. In
both cases we would need longitudinal data on enzyme ac-
tivity to estimate the impact of changes in enzyme activity
on changes in health outcomes.
Limitations of the study
The number of observations and study period are relatively
limited given the slow disease progression seen in Pompe
disease. However, these limitations are common for studies
of rare chronic diseases. This limitation could be rectified
by international studies that collect relevant patient data in
a standardized manner with a minimum loss to follow-up.
Another limitation of our study was lack of data on short-
ness of breath, which could therefore not be included in
the model.
Transferability of the model
This is the first study in which the Wilson-Cleary model is
applied to an orphan disease. Although our model is specif-
ically developed to describe and quantify the relationships
between specific levels of health concepts of Pompe disease
in adult patients, the approach used in this study can also
be applied to other Pompe patient populations, i.e. children
and infantile patients, or for other orphan diseases. Obvi-
ously, it is necessary to adapt the model to ensure that it
contains only relevant disease-specific information and
knowledge, although parts of the model developed here
for Pompe disease in adult patients may still be relevant.
To model Mucopolysaccharidosis type II for instance,
“physiological factors” might be expressed using joint
angle range and mental retardation can be used as a
measure for “functional health”. As another example,
Duchenne muscular dystrophy might be adequately repre-
sented using the current model if a factor for heart per-
formance were to be included. However, in all cases, the
application of the Wilson-Cleary model should be studied
for each disease separately.
Conclusions
The Wilson-Cleary health outcomes model is a helpful tool
for developing a conceptual model for Pompe disease. The
conceptual model provides a comprehensive overview of all
aspects of Pompe disease in adults, integrating subjective
and objective health outcomes in one model. This model
can be useful to clinicians and researchers who want to
explore how changes in specific clinical characteristics may
affect a patient’s overall health outcomes. In addition, the
model can be useful for policy makers who must consider
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bursement decisions about treatments for orphan diseases.
The approach used here provides a means to understand
the mechanisms that drive changes in health that may
occur both during natural course or if a drug is used to
treat patients.
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